Tara B Hendry-Hofer1, Alyssa E Witeof1, Dennean S Lippner2, Patrick C Ng1,3, Sari B Mahon4, Matthew Brenner4, Gary A Rockwood2, Vikhyat S Bebarta1,5. 1. a Department of Emergency Medicine and Toxicology , University of Colorado Anschutz Medical Campus , Aurora , C.O , U.S.A. 2. b Medical Toxicology Division, Biochemistry and Physiology Branch , US Army Medical Research Institute of Chemical Defense , Aberdeen Proving Ground, M.D , U.S.A. 3. c Rocky Mountain Poison and Drug Center , Denver Health and Hospital Authority , Denver , C.O , U.S.A. 4. d Beckman Laser Institute , University of California , Irvine , C.A , U.S.A. 5. e Colonel, USAF Reserve, Office of the Chief Scientist , San Antonio, T.X , U.S.A.
Abstract
BACKGROUND: Cyanide is a deadly compound used as a terrorist agent. Current FDA approved antidotes require intravenous administration, limiting their utility in a mass casualty scenario. Dimethyl trisulfide (DMTS), a sulfur-based molecule, binds cyanide converting it to the less toxic by-product thiocyanate. Studies evaluating efficacy in rodents have been performed, but a large, clinically relevant animal model has not been reported. OBJECTIVE: This study evaluates the efficacy of intramuscular DMTS on survival and clinical outcomes in a swine model of acute, severe cyanide toxicity. METHODS: Anesthetized swine were instrumented for continuous monitoring of hemodynamics. Prior to potassium cyanide infusion animals were acclimated and breathing spontaneously. At 5-minutes post-apnea animals were treated with DMTS or saline. Vital signs, hemodynamics, and laboratory values were evaluated at various time points. RESULTS: Baseline values and time to apnea were similar in both groups. Survival in the DMTS treated group was 83.3% and 0% in saline controls (p = .005). The DMTS group returned to breathing at a mean time of 19.3 ± 10 min after antidote, control animals did not return to breathing (CI difference 8.8, 29.8). At the end of the experiment or time of death, mean lactate was 9.41 mmol/L vs. 4.35 mmol/L (CI difference -10.94,0.82) in the saline and DMTS groups, respectively and pH was 7.20 vs. 7.37 (CI difference -0.04, 0.38). No adverse effects were observed at the injection site. CONCLUSION: Intramuscular administration of DMTS improves survival and clinical outcomes in our large animal swine model of acute cyanide toxicity.
BACKGROUND:Cyanide is a deadly compound used as a terrorist agent. Current FDA approved antidotes require intravenous administration, limiting their utility in a mass casualty scenario. Dimethyl trisulfide (DMTS), a sulfur-based molecule, binds cyanide converting it to the less toxic by-product thiocyanate. Studies evaluating efficacy in rodents have been performed, but a large, clinically relevant animal model has not been reported. OBJECTIVE: This study evaluates the efficacy of intramuscular DMTS on survival and clinical outcomes in a swine model of acute, severe cyanidetoxicity. METHODS: Anesthetized swine were instrumented for continuous monitoring of hemodynamics. Prior to potassium cyanide infusion animals were acclimated and breathing spontaneously. At 5-minutes post-apnea animals were treated with DMTS or saline. Vital signs, hemodynamics, and laboratory values were evaluated at various time points. RESULTS: Baseline values and time to apnea were similar in both groups. Survival in the DMTS treated group was 83.3% and 0% in saline controls (p = .005). The DMTS group returned to breathing at a mean time of 19.3 ± 10 min after antidote, control animals did not return to breathing (CI difference 8.8, 29.8). At the end of the experiment or time of death, mean lactate was 9.41 mmol/L vs. 4.35 mmol/L (CI difference -10.94,0.82) in the saline and DMTS groups, respectively and pH was 7.20 vs. 7.37 (CI difference -0.04, 0.38). No adverse effects were observed at the injection site. CONCLUSION: Intramuscular administration of DMTS improves survival and clinical outcomes in our large animal swine model of acute cyanidetoxicity.
Authors: Susan M DeLeon; Jason D Downey; Diane M Hildenberger; Melissa O Rhoomes; Lamont Booker; Gary A Rockwood; Kelly A Basi Journal: Clin Toxicol (Phila) Date: 2017-09-19 Impact factor: 4.467
Authors: Kristof Kovacs; Anna C Duke; Marla Shifflet; Brittany Winner; Stephen A Lee; Gary A Rockwood; Ilona Petrikovics Journal: Pharm Dev Technol Date: 2016-01-07 Impact factor: 3.133
Authors: Kristof Kovacs; Prashanth K Jayanna; Anna Duke; Brittany Winner; Melaeni Negrito; Siva Angalakurthi; Jorn C C Yu; Petra Füredi; Krisztina Ludányi; Peter Sipos; Gary A Rockwood; Ilona Petrikovics Journal: Curr Drug Deliv Date: 2016 Impact factor: 2.565
Authors: Matthew Brenner; Jae G Kim; Sari B Mahon; Jangwoen Lee; Kelly A Kreuter; William Blackledge; David Mukai; Steve Patterson; Othman Mohammad; Vijay S Sharma; Gerry R Boss Journal: Ann Emerg Med Date: 2010-01-04 Impact factor: 5.721
Authors: Lóránd Kiss; Alexandra Bocsik; Fruzsina R Walter; James Ross; Denise Brown; Brooke A Mendenhall; Sarah R Crews; Jana Lowry; Valerie Coronado; David E Thompson; Peter Sipos; Piroska Szabó-Révész; Mária A Deli; Ilona Petrikovics Journal: Toxicol Sci Date: 2017-12-01 Impact factor: 4.849
Authors: Matthew Brenner; Sarah M Azer; Kyung-Jin Oh; Chang Hoon Han; Jangwoen Lee; Sari B Mahon; Xiaohua Du; David Mukai; Tanya Burney; Mayer Saidian; Adriano Chan; Derek I Straker; Vikhyat S Bebarta; Gerry R Boss Journal: J Clin Toxicol Date: 2017-06-27
Authors: Tara B Hendry-Hofer; Alyssa E Witeof; Patrick C Ng; Sari B Mahon; Matthew Brenner; Gerry R Boss; Vikhyat S Bebarta Journal: Clin Toxicol (Phila) Date: 2019-04-22 Impact factor: 4.467
Authors: Patrick C Ng; Tara B Hendry-Hofer; Matthew Brenner; Sari B Mahon; Gerry R Boss; Joseph K Maddry; Vikhyat S Bebarta Journal: J Med Toxicol Date: 2021-04-05